IL-4R Antibody Variable Domains for Stable Multispecific Formats
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anti-IL-4R therapies for treating inflammatory and autoimmune disorders, such as atopic dermatitis, have limited efficacy and do not adequately address symptoms like itching, and there is a need for stable and potent antibody building blocks that can inhibit IL-4- and IL-13-mediated signaling and be incorporated into multispecific antibody formats.
Innovation Solution
Development of antibody variable domains based on the monoclonal rabbit antibody clone 44-34-C10, which exhibit high affinity for IL-4R, neutralize signaling with low IC50 values, and maintain stability, allowing incorporation into multispecific antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-IL-4R therapies are used, then IL-4R binding is achieved, but efficacy is limited and symptoms like itching are not adequately addressed
Solution Approach 1:
The patent combines multiple functional domains into a single multispecific antibody molecule that simultaneously binds IL-4R and other targets (such as IL-31R or FcRn). This merging of multiple therapeutic functions into one agent enhances overall efficacy and addresses multiple disease symptoms including itching, while improving upon the limitations of existing single-target therapies
Solution Approach 2:
The antibody variable domains are designed with universal applicability across multiple disease indications by targeting IL-4R which is involved in multiple inflammatory pathways. The multispecific format further extends this universality by enabling single molecule to address diverse symptoms (inflammation, itching, IgE regulation) across different allergic and autoimmune conditions
2Reliability
If antibody variable domains are developed for high affinity binding, then neutralization potency increases, but stability may be compromised
Solution Approach 1:
The patent optimizes multiple parameters simultaneously including affinity constants (KD < 1 nM), IC50 values (IL-4: < 10 ng/ml, IL-13: < 50 ng/ml), and thermal stability (Tm ≥ 60°C). Through systematic parameter optimization of the antibody variable domain sequences, the invention achieves both high neutralization potency and enhanced stability, resolving the trade-off between these critical properties
Solution Approach 2:
The multispecific antibody construct functions as a composite molecular entity combining IL-4R binding domains with additional functional domains (such as IL-31R binding or FcRn binding domains). This composite structure distributes functional demands across multiple domains, allowing each domain to be optimized for its specific function while maintaining overall molecular stability
3Object-generated harmful factors
If monoclonal antibodies are used to block IL-4R signaling, then Th2-driven inflammation is reduced, but response rates remain low to moderate
Solution Approach 1:
The patent merges IL-4R blockade function with additional therapeutic functions in a single multispecific antibody. By combining IL-4R binding domains with domains that bind other inflammatory targets (such as IL-31R for itching control) or enhance pharmacokinetics (FcRn binding), the invention achieves superior response rates by addressing multiple disease mechanisms simultaneously rather than relying on single-target blockade
Data Source
AI summary
The present invention relates to an antibody variable domain, which specifically binds to IL-4R, to multispecific antibodies comprising one or two of said antibody variable domains and at least one further binding domain that specifically binds to a target different from IL-4R. The present invention further relates a nucleic acid or two nucleic acids encoding said antibody variable domain or said multispecific antibody, vector(s) comprising said nucleic acid or said nucleic acids, host cell(s) comprising said nucleic acid or said nucleic acids or said vector(s), and a method of producing said antibody variable domain or said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said antibody variable domain or said multispecific antibody and to methods of use thereof.